Abstract: The present invention relates to a method for preparing organic compounds of formula (I) by reaction between a silylated formiate of formula (II) and an organic compound in the presence of a catalyst and optionally of an additive. The invention also relates to use of the method for preparing organic compounds of formula (I) for the preparation of reagents for fine chemistry and for heavy chemistry, as well as in the production of vitamins, pharmaceutical products, adhesives, acrylic fibres, synthetic leathers, and pesticides.
Type:
Grant
Filed:
August 7, 2017
Date of Patent:
February 27, 2024
Assignee:
Commissariat a l'Energie Atomique et aux Energies Alternatives
Abstract: A hydrophilic silicone, compositions comprising the same, and articles comprising the same are shown and described herein. The hydrophilic silicone is an ionically modified silicone compound wherein the compound comprises a zwitterionic moiety and has a net neutral charge. The hydrophilic silicone compounds may be provided as part of a composition, e.g., a composition suitable for forming a hydrogel, which may be employed to form a film material and even an article (e.g., in a contact lens).
Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.
Type:
Grant
Filed:
October 16, 2020
Date of Patent:
January 30, 2024
Assignees:
The Regents of the University of California, Atengen, Inc.
Inventors:
Hui Sun, Pu Sun, Guo Cheng, Adrian Chichuen Au, Ming Zhong
Abstract: The invention provides compositions and methods to treat diabetes with improved formulations in which metformin is combined with at least three antioxidants that contain a stabilizing heteroatom adjacent to a saturated carbon and which help maintain a balance between antioxidant and pro-oxidant properties. The antioxidants include at least the combination of taurine, citrulline and methylcobalamin, and optionally include melatonin. The composition provides management of blood glucose levels comparable to metformin in the same dose without antioxidants, without the phenomenon of undermining metformin performance that is commonly observed in the presence of co-administered antioxidants.
Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
Type:
Grant
Filed:
October 17, 2016
Date of Patent:
January 9, 2024
Assignee:
ModernaTX, Inc.
Inventors:
Gabor Butora, Matthew Stanton, Edward John Miracco
Abstract: The present invention provides compounds, compositions, and methods for the treatment of prostate cancers, preferably, advanced prostate cancers. The subject invention also provides compounds, compositions, and methods for preventing/slowing down/reducing the progress and proliferation of prostate cancer cells. The subject invention further provides compounds, compositions, and methods for inhibiting DNA repair within cancer cells to slow tumor growth, preferably, by inhibiting BER capacity, including pol ? and LIG I.
Type:
Grant
Filed:
October 21, 2022
Date of Patent:
December 12, 2023
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.
Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
Type:
Grant
Filed:
May 16, 2023
Date of Patent:
December 5, 2023
Assignee:
CureVac Manufacturing GmbH
Inventors:
Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
Abstract: Provided is an oxidizing composition, in which a liquid medium is substantially inert in the presence of an oxidizing electrophile contained in the liquid medium. The composition comprises (a) an oxidizing electrophile comprising a main group element in oxidized form and at least one conjugate anion of an oxygen acid; (b) a non-oxidizable liquid selected from a fluorinated hydrocarbon, a sulfone, a deactivated arene, a deactivated aliphatic, a deactivated heteroarene, a deactivated heteroaliphatic, and a combination thereof; and (c) optionally one or more salt additives. Further provided are a method of using the oxidizing composition to oxidize a substrate and a method of generating and/or regenerating an oxidizing electrophile comprising a main group element.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
November 14, 2023
Assignees:
University of Florida Research Foundation, Incorporated, Hyconix, Inc.
Inventors:
Roy A. Periana, Brian G. Hashiguchi, Michael M. Konnick
Abstract: Provided are methods for isolating biomolecules, such as nucleic acids and proteins, from a sample using a silica-containing surface and/or a high salt, low pH buffer.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
November 14, 2023
Assignee:
QIAGEN Sciences, LLC
Inventors:
Heather Callahan, Eddie Adams, Mark N. Brolaski, Victoria Nieciecki
Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
November 14, 2023
Assignee:
PMV PHARMACEUTICALS, INC.
Inventors:
Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
Type:
Grant
Filed:
November 24, 2021
Date of Patent:
November 7, 2023
Assignee:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Rachel Auzely-Velty, Tamiris Figueiredo, Laura Jing Jing, Craig Steven Harris, Jean-Guy Boiteau, Thibaut Gerfaud, Loic Tomas
Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.
Type:
Grant
Filed:
July 14, 2021
Date of Patent:
October 17, 2023
Assignee:
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Abstract: Diterminally silanol-modified perfluoropolyether compounds of the general formula (1) (wherein each R1 is independently an unsubstituted divalent hydrocarbon group of 1 to 10 carbon atoms, each R2 is independently a substituted or unsubstituted monovalent hydrocarbon group of 1 to 10 carbon atoms, Rf is a perfluoropolyether group, and ‘n’ is independently at each occurrence an integer from 0 to 8) are provided. Such compounds, when reacted as an intermediate with a reactive silicon compound, afford compounds of excellent durability.
Abstract: The disclosed lanthanide precursor compounds include a cyclopentadienyl ligand having at least one aliphatic group as a substituent and at least one bidentate ligand. These precursors are suitable for depositing lanthanide containing films.
Type:
Grant
Filed:
February 8, 2022
Date of Patent:
October 10, 2023
Assignees:
L'Air Liquide, Sociéte Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude, American Air Liquide, Inc.
Inventors:
Daehyeon Kim, Junhyun Song, Wontae Noh, Venkateswara R. Pallem
Abstract: Compounds and method of preparation of Si—X and Ge—X compounds (X?N, P, As and Sb) via dehydrogenative coupling between the corresponding unsubstituted silanes and amines (including ammonia) or phosphines catalyzed by metallic catalysts is described. This new approach is based on the catalytic dehydrogenative coupling of a Si—H and a X—H moiety to form a Si—X containing compound and hydrogen gas (X?N, P, As and Sb). The process can be catalyzed by transition metal heterogenous catalysts such as Ru(0) on carbon, Pd(0) on MgO) as well as transition metal organometallic complexes that act as homogeneous catalysts. The —Si—X products produced by dehydrogenative coupling are inherently halogen free. Said compounds can be useful for the deposition of thin films by chemical vapor deposition or atomic layer deposition of Si-containing films.
Type:
Grant
Filed:
February 4, 2022
Date of Patent:
October 10, 2023
Assignee:
L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude
Inventors:
Antonio Sanchez, Gennadiy Itov, Peng Zhang, Matthew Stephens, Manish Khandelwal
Abstract: Compositions comprising decitabine and tetrahydrouridine or 5-azacytidine and tetrahydrouridine for the treatment of cancer are disclosed. The compositions in the form of a pill is administered to a human subject sequentially or alternately guided by the measurement of predictive biomarkers.
Type:
Grant
Filed:
January 27, 2022
Date of Patent:
October 10, 2023
Assignee:
EPIDESTINY, INC.
Inventors:
Yogen Saunthararajah, Joseph Desimone, Henry Lau, Santhosh Vadivelu
Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
Type:
Grant
Filed:
September 13, 2021
Date of Patent:
October 10, 2023
Assignee:
Sage Therapeutics, Inc.
Inventors:
Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
Abstract: [Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding. [Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
October 3, 2023
Assignee:
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY